US regulators have approved AstraZeneca’s Xigduo XR, giving patients with diabetes type II access to the first once-daily pill combining the SGLT2 inhibitor dapagliflozin and metformin hydrochloride extended-release.

The US Food and Drug Administration has given the all clear for the drug’s use as an adjunct therapy to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin, which is also marketed standalone as Forxiga, and metformin is appropriate.

For more details, go to: http://www.pharmatimes.com/Article/14-10-30/AZ_bags_US_nod_for_Xigduo_XR.aspx